Amyndas Pharmaceuticals
is a Private company. Amyndas Pharmaceuticals has 7 followers on Owler. Amyndas Pharmaceuticals has an estimated revenue of <$1M and an estimate of less <10 employees.Amyndas Pharmaceuticals
is a Private company. Amyndas Pharmaceuticals has 7 followers on Owler. Amyndas Pharmaceuticals has an estimated revenue of <$1M and an estimate of less <10 employees.
Est. Annual Revenue
$ < 1M
Est. Employees
<10
News
Mar 19, 2021
MarketScreener
Amyndas Pharmaceuticals: Amyndas : Announces Positive Top-Line Phase 2 Results for Investigational AMY-101 in Adults With Periodontal Inflammation and Gingivitis
Jun 16, 2020
BioSpace
Amyndas Pharmaceuticals: Quartesian Announces Amyndas Partnership for COVID-19 Clinical Trial
Aug 28, 2019
Sciad Newswire
Press Release: Amyndas Pharmaceuticals : Amyndas Pharmaceuticals Initiates Phase 2a study of AMY-101 in adults with Periodontal inflammation and Gingivitis
Dec 13, 2018
Business Wire
Press Release: Amyndas Pharmaceuticals : Ischemia Reperfusion Injury Pipeline Insight Report, 2018 - ResearchAndMarkets.com
Mar 28, 2018
4-traders
Amyndas Pharmaceuticals: High Point Clinical Trials Center and Amyndas Pharmaceuticals Announce the Completion of the Complement C3 Inhibitor AMY-101 First in Human Study
Dec 13, 2017
Sciad Newswire
Press Release: Amyndas Pharmaceuticals : Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101
May 04, 2016
EIN Presswire
Press Release: Amyndas Pharmaceuticals : Glomerulonephritis Therapeutics Drugs and Companies Pipeline Market H1 2016
Dec 02, 2015
Business Wire
Press Release: Amyndas Pharmaceuticals : Research and Markets: Global Periodontitis Therapeutics Pipeline Review, H2 2015 - 7 Companies & 12 Drug Profiles
Aug 20, 2015
BUSINESS WIRE
Press Release: Amyndas Pharmaceuticals : Research and Markets: Ischemia - Pipeline Review, H1 2015